Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01415882 · ClinicalTrials.gov registry record · Phase 2
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
NCT01415882: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT01415882 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 165 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (24% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01415882, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
Study Summary
This phase II trial studies how well ixazomib citrate works in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) but is not resistant to bortezomib (refractory). Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
A confirmed response is defined as stringent complete response, complete response (CR), very good partial response, or partial response (PR) noted as the objective status on 2 separate evaluations while receiving ixazomib citrate with or without dexamethasone. The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. 95% confidence intervals for the true success proportion will be calculated by the exact binomial method.
Interventions
- DRUG Cyclophosphamide
- OTHER Laboratory Biomarker Analysis
- DRUG Dexamethasone
- BIOLOGICAL Daratumumab
- DRUG Ixazomib Citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2012-01-31 |
| Est. Completion | 2025-04-30 |
| Phase | Phase 2 |
What the finished NCT01415882 record still lists
NCT01415882 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (24% higher).
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01415882 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01415882 about?
NCT01415882 is a clinical study titled "Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib". This phase II trial studies how well ixazomib citrate works in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) but is not resistant to bortezomib (refractory). Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes need...
What is the current status of trial NCT01415882?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2012-01-31. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT01415882?
The interventions under investigation include: Cyclophosphamide (DRUG), Laboratory Biomarker Analysis (OTHER), Dexamethasone (DRUG), Daratumumab (BIOLOGICAL), Ixazomib Citrate (DRUG).
Who is sponsoring clinical trial NCT01415882?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01415882's enrollment target sits among peer trials
165 410th of 2000 higher than 1,588 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03351348 · 165 participants · Phase 3
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
- NCT03830320 · 165 participants · Phase 1
Positron Emission Tomography (PET) Imaging of Thrombosis
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI